These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
221 related items for PubMed ID: 17507922
1. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection. Lehman HP, Chen J, Gould AL, Kassekert R, Beninger PR, Carney R, Goldberg M, Goss MA, Kidos K, Sharrar RG, Shields K, Sweet A, Wiholm BE, Honig PK. Clin Pharmacol Ther; 2007 Aug; 82(2):173-80. PubMed ID: 17507922 [Abstract] [Full Text] [Related]
2. Decision support methods for the detection of adverse events in post-marketing data. Hauben M, Bate A. Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799 [Abstract] [Full Text] [Related]
3. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis. Hauben M, Vegni F, Reich L, Younus M. Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161 [Abstract] [Full Text] [Related]
5. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations. Brown JS, Kulldorff M, Petronis KR, Reynolds R, Chan KA, Davis RL, Graham D, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R. Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):226-34. PubMed ID: 19148879 [Abstract] [Full Text] [Related]
6. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R. Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500 [Abstract] [Full Text] [Related]
8. Disproportionality analysis for signal detection of implantable cardioverter-defibrillator-related adverse events in the Food and Drug Administration Medical Device Reporting System. Duggirala HJ, Herz ND, Caños DA, Sullivan RA, Schaaf R, Pinnow E, Marinac-Dabic D. Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):87-93. PubMed ID: 22095760 [Abstract] [Full Text] [Related]
12. Early postmarketing drug safety surveillance: data mining points to consider. Hauben M. Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626 [Abstract] [Full Text] [Related]
14. Detection of adverse drug reaction signals using an electronic health records database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) algorithm. Yoon D, Park MY, Choi NK, Park BJ, Kim JH, Park RW. Clin Pharmacol Ther; 2012 Mar; 91(3):467-74. PubMed ID: 22237257 [Abstract] [Full Text] [Related]
17. A conditional maximized sequential probability ratio test for pharmacovigilance. Li L, Kulldorff M. Stat Med; 2010 Jan 30; 29(2):284-95. PubMed ID: 19941282 [Abstract] [Full Text] [Related]
19. Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data. Rolka H, Bracy D, Russell C, Fram D, Ball R. Stat Med; 2005 Feb 28; 24(4):551-62. PubMed ID: 15678409 [Abstract] [Full Text] [Related]